The Centers for Medicare & Medicaid Services’ yesterday issued guidance regarding the calculation of a plan’s Medical Loss Ratio, which represents the percent of premium revenue that goes toward claims and activities that improve health care quality. CMS regulations require Medicaid and CHIP managed care plans to use an MLR target of 85 percent in developing rates, and to exclude prescription drug rebates from the claims costs used to calculate an MLR. CMS said the guidance clarifies that a prescription drug rebate means any price concession or discount received by the managed care plan or by its pharmacy benefit manager, regardless of who pays the rebate or discount. CMS Administrator Seema Verma expressed concern that some managed care plans are not accurately reporting pharmacy benefit “spread pricing” when they calculate and report MLRs. Spread pricing occurs when health plans contract with PBMs to manage their prescription drug benefits, and PBMs keep a portion of the amount paid to them by the health plans for prescription drugs instead of passing the full payments on to pharmacies.  

Related News Articles

Headline
The Department of Health and Human Services July 28 announced the creation of a $100 million pilot program to prevent, test for, treat and cure hepatitis C for…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Perspective
Public
The 2025 AHA Leadership Summit wrapped up on July 22, and as always, it was energizing and inspiring to connect with so many talented and dedicated people…
Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
Carolyn Bogard, DNP, R.N., director of care coordination and palliative care at El Camino Health, talks about her system’s use of data to harness the passion…
Headline
The Food and Drug Administration has identified a Class I recall of certain lots of Medline Industries Craniotomy Kits containing recalled Codman…